TAAR1: Potential Drug Targets for Cancer, Neurodegenerative Diseases and Autoimmune Disorders

Target Name: TAAR1

NCBI ID: G134864

TAAR1

TAAR1: Potential Drug Targets for Cancer, Neurodegenerative Diseases and Autoimmune Disorders

TAAR1 (TAR1) is a protein that is expressed in various tissues throughout the body, including the brain, heart, and lungs. It is a member of the TAR family of proteins, which are involved in the regulation of cell growth, differentiation, and survival.TAAR1 has been identified as a potential drug target due to its involvement in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the most significant functions of TAAR1 is its role in cell signaling. TAAR1 is a negative regulator of the PI3K/Akt signaling pathway, which is involved in the regulation of cell growth, survival, and differentiation. This means that when TAAR1 is activated, it works to inhibit the effects of PI3K/Akt signaling, which can lead to the inhibition of cell growth and survival.

TAAR1 has been shown to be involved in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, TAAR1 has been shown to be involved in the development and progression of brain tumors, such as neuroblastoma. Additionally, TAAR1 has been linked to the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

Another function of TAAR1 is its role in the regulation of cell death. TAAR1 is involved in the regulation of cell apoptosis, which is the process by which cells die naturally in response to various stimuli, such as UV radiation, infections, or injuries. When TAAR1 is activated, it works to prevent cell apoptosis, which can lead to the survival of damaged cells that could otherwise be terminated.

TAAR1 is also involved in the regulation of inflammation. TAAR1 has been shown to be involved in the regulation of the production of pro-inflammatory cytokines, which are involved in the inflammatory response. This means that when TAAR1 is activated, it works to prevent the production of pro-inflammatory cytokines, which can lead to the regulation of inflammation.

In conclusion, TAAR1 is a protein that is involved in several important functions in the regulation of cell growth, differentiation, and survival. Its involvement in the development and progression of cancer, neurodegenerative diseases, and autoimmune disorders makes it a potential drug target. Further research is needed to fully understand the role of TAAR1 in these diseases and to develop effective treatments.

Protein Name: Trace Amine Associated Receptor 1

Functions: Receptor for trace amines, including beta-phenylethylamine (b-PEA), p-tyramine (p-TYR), octopamine and tryptamine, with highest affinity for b-PEA and p-TYR. Unresponsive to classical biogenic amines, such as epinephrine and histamine and only partially activated by dopamine and serotonin. Trace amines are biogenic amines present in very low levels in mammalian tissues. Although some trace amines have clearly defined roles as neurotransmitters in invertebrates, the extent to which they function as true neurotransmitters in vertebrates has remained speculative. Trace amines are likely to be involved in a variety of physiological functions that have yet to be fully understood. The signal transduced by this receptor is mediated by the G(s)-class of G-proteins which activate adenylate cyclase

The "TAAR1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TAAR1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets